Oncologic outcomes following radical prostatectomy with intraoperative cell salvage

Michael A. Gorin, Ahmed Eldefrawy, Murugesan Manoharan, Mark S. Soloway

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To evaluate oncologic outcomes following the use of intraoperative cell salvage (IOCS) as a blood loss management strategy during open radical prostatectomy (RP). Methods: We retrospectively reviewed all open retropubic RP cases performed by a single surgeon. Patients were identified who received IOCS blood and evaluated for an increased risk of biochemical recurrence (BCR) and overall mortality. Results: The study cohort consisted of 1,862 men, 395 (21.2%) of whom received IOCS blood. At a median follow-up of 47.0 months, men who received IOCS blood were not at an increased risk of BCR (P = 0.323) or all-cause mortality (P = 0.892). IOCS use did not confer an increased risk of BCR within any D'Amico preoperative risk category (low risk, P = 0.592; intermediate risk, P = 0.107; and high risk, P = 0.697). Conclusions: IOCS is safe for the management of blood loss during RP. At long-term follow-up, IOCS use was not associated with an increased risk of BCR or death. While it remains preferable to avoid any form of blood transfusion, we advocate for the use of IOCS in place of allogeneic blood. These conclusions are drawn from our study of the largest and longest followed cohort patients who received IOCS blood during RP.

Original languageEnglish
Pages (from-to)379-383
Number of pages5
JournalWorld Journal of Urology
Volume30
Issue number3
DOIs
StatePublished - Jun 1 2012

Fingerprint

Prostatectomy
Operative Blood Salvage
Recurrence
Mortality
Blood Transfusion
Cohort Studies

Keywords

  • Biochemical recurrence
  • Blood transfusion
  • Intraoperative cell salvage
  • Prostate cancer
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Oncologic outcomes following radical prostatectomy with intraoperative cell salvage. / Gorin, Michael A.; Eldefrawy, Ahmed; Manoharan, Murugesan; Soloway, Mark S.

In: World Journal of Urology, Vol. 30, No. 3, 01.06.2012, p. 379-383.

Research output: Contribution to journalArticle

Gorin, Michael A. ; Eldefrawy, Ahmed ; Manoharan, Murugesan ; Soloway, Mark S. / Oncologic outcomes following radical prostatectomy with intraoperative cell salvage. In: World Journal of Urology. 2012 ; Vol. 30, No. 3. pp. 379-383.
@article{c497f23b2b88404aac3dc18e2799a341,
title = "Oncologic outcomes following radical prostatectomy with intraoperative cell salvage",
abstract = "Purpose: To evaluate oncologic outcomes following the use of intraoperative cell salvage (IOCS) as a blood loss management strategy during open radical prostatectomy (RP). Methods: We retrospectively reviewed all open retropubic RP cases performed by a single surgeon. Patients were identified who received IOCS blood and evaluated for an increased risk of biochemical recurrence (BCR) and overall mortality. Results: The study cohort consisted of 1,862 men, 395 (21.2{\%}) of whom received IOCS blood. At a median follow-up of 47.0 months, men who received IOCS blood were not at an increased risk of BCR (P = 0.323) or all-cause mortality (P = 0.892). IOCS use did not confer an increased risk of BCR within any D'Amico preoperative risk category (low risk, P = 0.592; intermediate risk, P = 0.107; and high risk, P = 0.697). Conclusions: IOCS is safe for the management of blood loss during RP. At long-term follow-up, IOCS use was not associated with an increased risk of BCR or death. While it remains preferable to avoid any form of blood transfusion, we advocate for the use of IOCS in place of allogeneic blood. These conclusions are drawn from our study of the largest and longest followed cohort patients who received IOCS blood during RP.",
keywords = "Biochemical recurrence, Blood transfusion, Intraoperative cell salvage, Prostate cancer, Radical prostatectomy",
author = "Gorin, {Michael A.} and Ahmed Eldefrawy and Murugesan Manoharan and Soloway, {Mark S.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s00345-011-0746-4",
language = "English",
volume = "30",
pages = "379--383",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Oncologic outcomes following radical prostatectomy with intraoperative cell salvage

AU - Gorin, Michael A.

AU - Eldefrawy, Ahmed

AU - Manoharan, Murugesan

AU - Soloway, Mark S.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Purpose: To evaluate oncologic outcomes following the use of intraoperative cell salvage (IOCS) as a blood loss management strategy during open radical prostatectomy (RP). Methods: We retrospectively reviewed all open retropubic RP cases performed by a single surgeon. Patients were identified who received IOCS blood and evaluated for an increased risk of biochemical recurrence (BCR) and overall mortality. Results: The study cohort consisted of 1,862 men, 395 (21.2%) of whom received IOCS blood. At a median follow-up of 47.0 months, men who received IOCS blood were not at an increased risk of BCR (P = 0.323) or all-cause mortality (P = 0.892). IOCS use did not confer an increased risk of BCR within any D'Amico preoperative risk category (low risk, P = 0.592; intermediate risk, P = 0.107; and high risk, P = 0.697). Conclusions: IOCS is safe for the management of blood loss during RP. At long-term follow-up, IOCS use was not associated with an increased risk of BCR or death. While it remains preferable to avoid any form of blood transfusion, we advocate for the use of IOCS in place of allogeneic blood. These conclusions are drawn from our study of the largest and longest followed cohort patients who received IOCS blood during RP.

AB - Purpose: To evaluate oncologic outcomes following the use of intraoperative cell salvage (IOCS) as a blood loss management strategy during open radical prostatectomy (RP). Methods: We retrospectively reviewed all open retropubic RP cases performed by a single surgeon. Patients were identified who received IOCS blood and evaluated for an increased risk of biochemical recurrence (BCR) and overall mortality. Results: The study cohort consisted of 1,862 men, 395 (21.2%) of whom received IOCS blood. At a median follow-up of 47.0 months, men who received IOCS blood were not at an increased risk of BCR (P = 0.323) or all-cause mortality (P = 0.892). IOCS use did not confer an increased risk of BCR within any D'Amico preoperative risk category (low risk, P = 0.592; intermediate risk, P = 0.107; and high risk, P = 0.697). Conclusions: IOCS is safe for the management of blood loss during RP. At long-term follow-up, IOCS use was not associated with an increased risk of BCR or death. While it remains preferable to avoid any form of blood transfusion, we advocate for the use of IOCS in place of allogeneic blood. These conclusions are drawn from our study of the largest and longest followed cohort patients who received IOCS blood during RP.

KW - Biochemical recurrence

KW - Blood transfusion

KW - Intraoperative cell salvage

KW - Prostate cancer

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84861614668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861614668&partnerID=8YFLogxK

U2 - 10.1007/s00345-011-0746-4

DO - 10.1007/s00345-011-0746-4

M3 - Article

C2 - 21847657

AN - SCOPUS:84861614668

VL - 30

SP - 379

EP - 383

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -